{
    "items": "157",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Johnson & Johnson  ( JNJ )  Rises As Market Takes a Dip: Key Facts",
            "url": "https://www.zacks.com/stock/news/2205270/johnson-johnson-jnj-rises-as-market-takes-a-dip-key-facts",
            "time_published": "20240103T224520",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.97, denoting a +0.63% change from the preceding trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default49.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.145177,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.605266",
                    "ticker_sentiment_score": "0.126404",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Trims Losses After Fed Minutes; What The Bad Santa Rally Means For Indexes",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-trims-losses-after-fed-minutes-what-the-bad-santa-rally-means-for-indexes/",
            "time_published": "20240103T201700",
            "authors": [
                "Investor's Business Daily",
                "JUAN CARLOS ARANCIBIA"
            ],
            "summary": "Stock Market Trims Losses After Fed Minutes. What The Bad Santa Rally Means For Indexes Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-nyse2-0122-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.128475,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.179343",
                    "ticker_sentiment_score": "-0.1809",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "-0.118997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "-0.118997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "S",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "-0.105001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.112157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.112157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "-0.105001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "-0.118997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.12013",
                    "ticker_sentiment_score": "0.10532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYAOF",
                    "relevance_score": "0.060236",
                    "ticker_sentiment_score": "0.093",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will 2024 Be The Year Of The Other 493?",
            "url": "https://www.benzinga.com/markets/24/01/36476280/will-2024-be-the-year-of-the-other-493",
            "time_published": "20240103T190842",
            "authors": [
                "Real Investment Advice"
            ],
            "summary": "As we welcome in 2024, one of the most critical questions facing investors is which stocks and sectors will beat the market. Can the Magnificent 7 retain its crown? Or will some subset of the 493 other S&P 500 stocks and their neglected sectors take the throne in 2024? The Magnificent 7 stole the ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/03/nicholas-cappello-wb63zqj5gne-unsplash_12.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999965"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.19366,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.247442",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.247442",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.245693",
                    "ticker_sentiment_score": "0.193291",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.247442",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALB",
                    "relevance_score": "0.211498",
                    "ticker_sentiment_score": "0.04408",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.093705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.093705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.034375",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.247442",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns - Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36473452/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-reven",
            "time_published": "20240103T172930",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "BofA Securities downgraded Bristol-Myers Squibb & Co BMY, noting that initially, the analyst believed that Bristol's loss of exclusivity ( LOEs ) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate for these losses and boost ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/03/bmy.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.241436,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.56415",
                    "ticker_sentiment_score": "0.197908",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.282842",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.282842",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharmaceutical Drug Delivery Market Set For Robust Growth: Market Size To Reach $2337 Billion By 2028 As Per The Business Research Company's Pharmaceutical Drug Delivery Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/01/g36473207/pharmaceutical-drug-delivery-market-set-for-robust-growth-market-size-to-reach-2337-billion-by-202",
            "time_published": "20240103T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's pharmaceutical drug delivery global market report 2024, the global pharmaceutical drug delivery market has exhibited robust growth, expanding from $1711.47 billion in 2023 to an estimated $1816.05 billion in 2024, ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.332912,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.04882",
                    "ticker_sentiment_score": "0.091119",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.04882",
                    "ticker_sentiment_score": "0.091119",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04882",
                    "ticker_sentiment_score": "0.091119",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives",
            "url": "https://www.prnewswire.com/news-releases/medytox-inc-announces-the-formation-of-luvantas-subsidiary-and-appointment-of-key-executives-302025050.html",
            "time_published": "20240103T134500",
            "authors": [
                "Inc",
                "Luvantas"
            ],
            "summary": "IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. ( www.luvantas.com ) as its wholly-owned North American subsidiary.",
            "banner_image": "https://mma.prnewswire.com/media/2309850/Luvantas_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.242939,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.064973",
                    "ticker_sentiment_score": "0.092192",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Is TikTok Parent ByteDance Moving Into Biology, Chemistry And Drug Discovery?",
            "url": "https://www.forbes.com/sites/alexandralevine/2024/01/02/tiktok-bytedance-pharmaceuticals-drug-discovery-science-biology-chemistry-ai-china/",
            "time_published": "20240103T113000",
            "authors": [
                "Alexandra S. Levine"
            ],
            "summary": "TikTok's Chinese parent is beginning to recruit across the U.S. for experts in science and healthcare disciplines far afield from social media. Its motives are unclear.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6594bb2c97c00e37e55b0c79/0x0.jpg?format=jpg&crop=1920,1080,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.206995,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.10389",
                    "ticker_sentiment_score": "0.158286",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.157007",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LTTHF",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.086589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.026042",
                    "ticker_sentiment_score": "0.108238",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 No-Brainer Stocks to Buy With $1,000 Right Now for the New Year",
            "url": "https://www.fool.com/investing/2024/01/03/3-no-brainer-stocks-to-buy-with-1000-right-now/",
            "time_published": "20240103T102100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "A modest amount of money can go a long way when it's put to work in industry-leading, time-tested businesses with well-defined catalysts.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759756%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997405"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                }
            ],
            "overall_sentiment_score": 0.155262,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.204565",
                    "ticker_sentiment_score": "0.140067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.029545",
                    "ticker_sentiment_score": "0.033514",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.232996",
                    "ticker_sentiment_score": "0.223562",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "-0.051886",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "10 things turning 100 in 2024, from Band-Aids to Popsicles",
            "url": "https://www.businessinsider.com/inventions-brands-events-100-years-ago-2024-1",
            "time_published": "20240102T212600",
            "authors": [
                "Talia Lakritz"
            ],
            "summary": "Things invented 100 years ago, turning 100 in 2024 - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.007075,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KMB",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "0.04046",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.283323",
                    "ticker_sentiment_score": "0.138721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "-0.045114",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Shareholders' Class Action Lawsuit Gets Nod from Federal Judge - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/24/01/36455727/johnson-johnson-shareholders-class-action-lawsuit-gets-nod-from-federal-judge",
            "time_published": "20240102T190130",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A federal judge's ruling in Trenton, New Jersey, has paved the way for Johnson & Johnson JNJ shareholders to collectively proceed with a lawsuit alleging the company concealed information about asbestos contamination in its talc products. U.S.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/02/jnjioffice3.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.117439,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.386875",
                    "ticker_sentiment_score": "-0.138228",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Travel Updates: Gatwick Hikes Drop-Off Fee",
            "url": "https://www.forbes.com/uk/advisor/travel-insurance/2024/01/02/travel-latest-news/",
            "time_published": "20240102T180148",
            "authors": [
                "Kevin Pratt"
            ],
            "summary": "2 January: Minimum Charge To Rise 20% To £6 For 10 Minutes Gatwick Airport is increasing its minimum drop-off charge by 20% from 5 January, when it will increase from £5 to £6. The minimum charge covers the first 10 minutes and must be paid by midnight the day after the visit.",
            "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/uk/advisor/wp-content/uploads/2022/02/ET-Ski-Resort-Map.jpg",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.007163,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DRTGF",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "-0.050149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAL",
                    "relevance_score": "0.001803",
                    "ticker_sentiment_score": "0.060776",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.004506",
                    "ticker_sentiment_score": "0.034618",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.002704",
                    "ticker_sentiment_score": "0.054221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHTDF",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "0.124796",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "0.01804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.004506",
                    "ticker_sentiment_score": "0.034618",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "-0.150718",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "YUGVF",
                    "relevance_score": "0.001803",
                    "ticker_sentiment_score": "0.049842",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "0.01804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.004506",
                    "ticker_sentiment_score": "0.034618",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RYAOF",
                    "relevance_score": "0.003605",
                    "ticker_sentiment_score": "-0.032104",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.000901",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "MeiraGTx  ( MGTX )  Stock Surges 35% in a Month: Here's Why",
            "url": "https://www.zacks.com/stock/news/2204585/meiragtx-mgtx-stock-surges-35-in-a-month-heres-why",
            "time_published": "20240102T171700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.126725,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MGTX",
                    "relevance_score": "0.665629",
                    "ticker_sentiment_score": "0.269937",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.289576",
                    "ticker_sentiment_score": "0.07981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.118064",
                    "ticker_sentiment_score": "0.110221",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.344074",
                    "ticker_sentiment_score": "0.127683",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why You Should Retain Medtronic  ( MDT )  Stock for Now",
            "url": "https://www.zacks.com/stock/news/2204570/heres-why-you-should-retain-medtronic-mdt-stock-for-now",
            "time_published": "20240102T171000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5e/1093.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995869"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.23334,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SYK",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "0.097986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "0.097986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04823",
                    "ticker_sentiment_score": "0.097986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.143987",
                    "ticker_sentiment_score": "0.055556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.494156",
                    "ticker_sentiment_score": "0.273372",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HAE",
                    "relevance_score": "0.237668",
                    "ticker_sentiment_score": "0.164475",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.106025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference",
            "url": "https://www.globenewswire.com/news-release/2024/01/02/2802628/0/en/Perspective-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html",
            "time_published": "20240102T130000",
            "authors": [
                "Inc.",
                "Perspective Therapeutics"
            ],
            "summary": "SEATTLE, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Perspective Therapeutics, Inc. ( \"Perspective\" or \"the Company\" ) ( NYSE AMERICAN: CATX ) , today announced that Thijs Spoor, the Company's Chief Executive Officer, will present at the 42nd Annual J.P.",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/e8b42463-3d31-441e-8c09-6b88826fe1c6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.168717,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.038407",
                    "ticker_sentiment_score": "0.204125",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.038407",
                    "ticker_sentiment_score": "0.204125",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.038407",
                    "ticker_sentiment_score": "0.204125",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "XORTX Welcomes New Member to the Board of Directors",
            "url": "https://www.globenewswire.com/news-release/2024/01/02/2802570/0/en/XORTX-Welcomes-New-Member-to-the-Board-of-Directors.html",
            "time_published": "20240102T120000",
            "authors": [
                "XORTX Therapeutics Inc."
            ],
            "summary": "CALGARY, Alberta, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( \"XORTX\" or the \"Company\" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/9898c4f8-b373-438a-abfa-709c4372a061",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.165514,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PODD",
                    "relevance_score": "0.052918",
                    "ticker_sentiment_score": "0.052981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.052918",
                    "ticker_sentiment_score": "0.052981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KALV",
                    "relevance_score": "0.052918",
                    "ticker_sentiment_score": "0.052981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.052918",
                    "ticker_sentiment_score": "0.052981",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XRTX",
                    "relevance_score": "0.157827",
                    "ticker_sentiment_score": "0.28239",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( NYSE:JNJ )  Downgraded by StockNews.com to \"Buy\"",
            "url": "https://www.defenseworld.net/2024/01/02/johnson-johnson-nysejnj-downgraded-by-stocknews-com-to-buy.html",
            "time_published": "20240102T072246",
            "authors": [
                "Defense World Staff"
            ],
            "summary": "StockNews.com cut shares of Johnson & Johnson ( NYSE:JNJ - Free Report ) from a strong-buy rating to a buy rating in a report released on Monday morning. Other equities analysts also recently issued research reports about the stock.",
            "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo.png?v=20221020135923",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.defenseworld.net",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.24419,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "RBCPF",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.007998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.007998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.007998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.82927",
                    "ticker_sentiment_score": "0.414319",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "PLATINUM EQUITY TO ACQUIRE HORIZON ORGANIC AND WALLABY FROM DANONE",
            "url": "https://www.prnewswire.com/news-releases/platinum-equity-to-acquire-horizon-organic-and-wallaby-from-danone-302024315.html",
            "time_published": "20240102T043500",
            "authors": [
                "Platinum Equity"
            ],
            "summary": "Leading dairy products brands projected to benefit from Platinum Equity's carve-out experience and operational expertise LOS ANGELES, Jan. 1, 2024 /PRNewswire/ -- Platinum Equity today announced the signing of a definitive agreement to acquire Horizon Organic and Wallaby from Danone.",
            "banner_image": "https://mma.prnewswire.com/media/1557720/Platinum_Equity_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99977"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.306214,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MCO",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.172582",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IR",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.037051",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RGBD",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.172582",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EMR",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.037051",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.037051",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It",
            "url": "https://www.zacks.com/stock/news/2204062/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it",
            "time_published": "20240101T140012",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.228807,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.474958",
                    "ticker_sentiment_score": "0.13886",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet the 2024 Dogs of the Dow",
            "url": "https://www.fool.com/investing/2024/01/01/meet-the-2024-dogs-of-the-dow/",
            "time_published": "20240101T094600",
            "authors": [
                "Dan Caplinger"
            ],
            "summary": "2023 was another tough year for this popular investing strategy, but fans are hoping for better results in the coming year.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759686%2Fdogs-in-basket-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.156823,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.094691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.013152",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.209956",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "0.209956",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.081217",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Beaten-Down Dow Jones Stocks That Dividend Investors Should Scoop Up in 2024",
            "url": "https://www.fool.com/investing/2023/12/31/3-beaten-down-dow-jones-stocks-dividend-investors/",
            "time_published": "20231231T124400",
            "authors": [
                "Matthew DiLallo"
            ],
            "summary": "These \"Dogs of the Dow\" offer attractive dividend yields and upside potential.",
            "banner_image": "https://g.foolcdn.com/editorial/images/759636/a-hand-putting-another-coin-on-a-rising-stack-next-to-a-rising-money-chart.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.297347,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.094204",
                    "ticker_sentiment_score": "0.103366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.277433",
                    "ticker_sentiment_score": "0.266577",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.09857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.277433",
                    "ticker_sentiment_score": "0.171156",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.094204",
                    "ticker_sentiment_score": "0.03679",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jimmy Buffett, Gordon Moore And The Other Billionaires Who Died In 2023",
            "url": "https://www.forbes.com/sites/jemimadenham/2023/12/31/jimmy-buffett-gordon-moore-and-the-other-billionaires-who-died-in-2023/",
            "time_published": "20231231T113000",
            "authors": [
                "Jemima Denham"
            ],
            "summary": "Some larger than life personalities among the billionaire ranks died in 2023, including Jimmy Buffett, who turned his Margaritaville song into a lifestyle empire. cruise-ship-singer-turned-media mogul and Italian prime minister Silvio Berlusconi.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6584666da033ad15caa944b2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999941"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.059503,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CELH",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.128528",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IHRT",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "-0.006854",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WUXAY",
                    "relevance_score": "0.028729",
                    "ticker_sentiment_score": "0.059633",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "-0.106831",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.049917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNTMF",
                    "relevance_score": "0.043082",
                    "ticker_sentiment_score": "-0.019887",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FXNC",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "-0.017604",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.028729",
                    "ticker_sentiment_score": "0.027317",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.054896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.075837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NGCRF",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.035964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPB",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "-0.005892",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BTI",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.032985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.059919",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.028729",
                    "ticker_sentiment_score": "0.038776",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAHMF",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.055909",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "-0.005892",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSBHF",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.055909",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DENN",
                    "relevance_score": "0.014367",
                    "ticker_sentiment_score": "0.103249",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Best Warren Buffett Stocks to Buy for the Long Haul",
            "url": "https://www.fool.com/investing/2023/12/30/2-best-warren-buffett-stocks-to-buy-for-the-long/",
            "time_published": "20231230T131500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These companies need no introduction.",
            "banner_image": "https://media.ycharts.com/charts/d2c9a30539d16f42d92b7ad1a78a6296.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.308892,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.461889",
                    "ticker_sentiment_score": "0.355779",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.180726",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.304787",
                    "ticker_sentiment_score": "0.288497",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Judge certifies Johnson & Johnson shareholder class action over talc disclosures",
            "url": "https://www.foxbusiness.com/markets/judge-certifies-johnson-johnson-shareholder-class-action-talc-disclosures",
            "time_published": "20231229T231000",
            "authors": [
                "Reuters"
            ],
            "summary": "A federal judge said Johnson & Johnson shareholders may pursue as a class action their lawsuit accusing the company of fraudulently concealing how its talc products were contaminated by cancer-causing asbestos. U.S.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/3a1370e8-f94f-4a3a-86f5-63eecf90b0ce/1c8b901b-9287-485f-9bbd-7ec66869045e/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.165362,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.226301",
                    "ticker_sentiment_score": "-0.050515",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Unpacking the Latest Options Trading Trends in Johnson & Johnson - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/markets/options/23/12/36431124/unpacking-the-latest-options-trading-trends-in-johnson-johnson",
            "time_published": "20231229T174558",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bearish stance on Johnson & Johnson JNJ. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.196019,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "0.139677",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.069697",
                    "ticker_sentiment_score": "-0.111484",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.568819",
                    "ticker_sentiment_score": "0.319038",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "There Are Only 5 Dow Stocks I Wouldn't Buy in 2024",
            "url": "https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/",
            "time_published": "20231229T150000",
            "authors": [
                "Daniel Foelber"
            ],
            "summary": "There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759306%2Fgettyimages-1413763041-1200x800-5b2df79.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999982"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                }
            ],
            "overall_sentiment_score": 0.279781,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.23907",
                    "ticker_sentiment_score": "0.182253",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "0.061692",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "-0.087695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "-0.087695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.19231",
                    "ticker_sentiment_score": "0.149396",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "0.088087",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMI",
                    "relevance_score": "0.096866",
                    "ticker_sentiment_score": "0.180141",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "-0.064554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "-0.087695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "0.05482",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "0.025319",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.144853",
                    "ticker_sentiment_score": "0.156924",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "-0.087695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.096866",
                    "ticker_sentiment_score": "0.005339",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UPS",
                    "relevance_score": "0.096866",
                    "ticker_sentiment_score": "0.180141",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "0.129934",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.048523",
                    "ticker_sentiment_score": "-0.087695",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Top Dividend Stocks I Can't Wait to Buy in 2024",
            "url": "https://www.fool.com/investing/2023/12/29/3-top-dividend-stocks-i-cant-wait-to-buy-in-2024/",
            "time_published": "20231229T124000",
            "authors": [
                "Matthew DiLallo"
            ],
            "summary": "These companies will help me reach my income goals in 2024.",
            "banner_image": "https://g.foolcdn.com/editorial/images/759538/a-small-chalk-board-with-passive-income-written-out-in-near-stacks-of-100-bills.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.432928,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.388018",
                    "ticker_sentiment_score": "0.544824",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VICI",
                    "relevance_score": "0.282886",
                    "ticker_sentiment_score": "0.488021",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CWEN",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.297295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.173998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is iShares Core High Dividend ETF  ( HDV )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2203479/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now",
            "time_published": "20231229T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default103.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999996"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.338369,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "0.083972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.172377",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.066792",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.066792",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.066792",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Laps the Stock Market: Here's Why",
            "url": "https://www.zacks.com/stock/news/2203354/johnson-johnson-jnj-laps-the-stock-market-heres-why",
            "time_published": "20231228T224517",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $156.58, indicating a +0.15% shift from the previous trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default180.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.208548,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.519002",
                    "ticker_sentiment_score": "0.179476",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Contagious Opportunities: Norovirus Cases Are On The Rise, These Are The Stocks That May Be Impacted - Johnson & Johnson  ( NYSE:JNJ ) , Darden Restaurants  ( NYSE:DRI ) , Clorox  ( NYSE:CLX ) ",
            "url": "https://www.benzinga.com/general/health-care/23/12/36414917/contagious-opportunities-norovirus-cases-are-on-the-rise-these-are-the-stocks-that-may-be-imp",
            "time_published": "20231228T194206",
            "authors": [
                "Aaron Bry"
            ],
            "summary": "Cases of norovirus, sometimes called the \"winter vomiting disease,\" are on the rise in multiple states throughout the U.S. The virus causes stomach pain, vomiting and diarrhea and has been linked to outbreaks at restaurants such as the one at a sushi restaurant in North Carolina that infected ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/28/shutterstock_2025161825.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.147876,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CLX",
                    "relevance_score": "0.499789",
                    "ticker_sentiment_score": "-0.144205",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRI",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.017681",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.499789",
                    "ticker_sentiment_score": "-0.210934",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Investor Michael Farr is back with his top 10 stocks he's buying for 2024, and the tilt is defensive",
            "url": "https://www.cnbc.com/2023/12/28/investor-michael-farr-is-back-with-his-top-10-stocks-hes-buying-for-2024-and-the-tilt-is-defensive.html",
            "time_published": "20231228T190255",
            "authors": [
                "Michael K. Farr"
            ],
            "summary": "This year's list is a bit more defensive than in years past and has a focus on earnings growth.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107350212-17031021711703102168-32534354100-1080pnbcnews.jpg?v=1703102170&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Investing",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.266071,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.12084",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.264629",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VMI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.098696",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.034382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.034382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.264629",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DIS",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.231498",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 - AstraZeneca  ( NASDAQ:AZN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36410940/pharmaceutical-giants-brace-for-showdown-as-medicare-drug-price-negotiations-are-poised-for-2024",
            "time_published": "20231228T142124",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first glimpse into how much Medicare can leverage its newfound power to negotiate down drug prices.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/28/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.167646,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.239305",
                    "ticker_sentiment_score": "0.028897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.239305",
                    "ticker_sentiment_score": "0.028897",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts - Abbott Laboratories  ( NYSE:ABT ) , Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/news/23/12/36409451/eli-lilly-johnson-johnson-and-other-health-care-stocks-from-wall-streets-most-accurate-analysts",
            "time_published": "20231228T123313",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/28/image37.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.752319"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.1564,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.154951",
                    "ticker_sentiment_score": "0.074886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "-0.044126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "-0.106435",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "0.17572",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "0.070882",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MGTX",
                    "relevance_score": "0.077845",
                    "ticker_sentiment_score": "0.17572",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Biden administration's Medicare drug price negotiations will face major tests in 2024",
            "url": "https://www.cnbc.com/2023/12/28/medicare-drug-price-negotiations-whats-ahead-in-2024.html",
            "time_published": "20231228T120001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Next year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by the end of the decade.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1702616299&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.021634,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.166075",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.173879",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.088039",
                    "ticker_sentiment_score": "0.008287",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058759",
                    "ticker_sentiment_score": "-0.059983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "-0.026135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "-0.026135",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Warren Buffett Dumped These 2 Top Dividend Stocks. Should You Follow His Lead?",
            "url": "https://www.fool.com/investing/2023/12/28/warren-buffett-dumped-these-2-top-dividend-stocks/",
            "time_published": "20231228T103900",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Buffett didn't say why he closed positions in two stocks with underlying businesses that are doing well at the moment.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759334%2Fwarren-buffett-fool-may-2015.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.972756"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.241895,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "0.006362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CURN",
                    "relevance_score": "0.046363",
                    "ticker_sentiment_score": "-0.173351",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.046363",
                    "ticker_sentiment_score": "0.151381",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.17944",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "THE SKIN OF COLOR SOCIETY  ( SOCS )  REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR",
            "url": "https://markets.businessinsider.com/news/stocks/the-skin-of-color-society-socs-reports-a-banner-year-of-progress-toward-greater-diversity-inclusion-in-dermatology-and-health-equity-for-patients-of-color-1032928334",
            "time_published": "20231227T151000",
            "authors": [
                "markets.businessinsider.com"
            ],
            "summary": "THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR ...",
            "banner_image": "https://mma.prnewswire.com/media/2307927/SOC_8.jpg",
            "source": "Business Insider",
            "category_within_source": "RSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.383331,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.026127",
                    "ticker_sentiment_score": "0.27876",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SSKN",
                    "relevance_score": "0.026127",
                    "ticker_sentiment_score": "0.143497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.078269",
                    "ticker_sentiment_score": "0.264914",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARQT",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.304844",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.239708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.122732",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.078269",
                    "ticker_sentiment_score": "0.264914",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EOLS",
                    "relevance_score": "0.026127",
                    "ticker_sentiment_score": "0.143497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.026127",
                    "ticker_sentiment_score": "0.31383",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.026127",
                    "ticker_sentiment_score": "0.143497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INCY",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.239708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.052226",
                    "ticker_sentiment_score": "0.207643",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RCEL",
                    "relevance_score": "0.026127",
                    "ticker_sentiment_score": "0.143497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.078269",
                    "ticker_sentiment_score": "0.211482",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Avalo Therapeutics Announces 1-for-240 Reverse Stock Split",
            "url": "https://www.globenewswire.com/news-release/2023/12/27/2801310/0/en/Avalo-Therapeutics-Announces-1-for-240-Reverse-Stock-Split.html",
            "time_published": "20231227T120000",
            "authors": [
                "Avalo Therapeutics"
            ],
            "summary": "WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. ( Nasdaq: AVTX ) today announced a 1-for-240 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/950a0fc1-6e06-40b5-9adc-6d3d9f2d5e78",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.084262,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CLDX",
                    "relevance_score": "0.039811",
                    "ticker_sentiment_score": "0.120526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.039811",
                    "ticker_sentiment_score": "0.120526",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVTX",
                    "relevance_score": "0.158259",
                    "ticker_sentiment_score": "0.112951",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.039811",
                    "ticker_sentiment_score": "0.120526",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Time to Buy the Dow Jones' 3 Worst Performing Stocks This Year?",
            "url": "https://www.fool.com/investing/2023/12/27/is-it-time-to-buy-the-dow-jones-3-worst-performing/",
            "time_published": "20231227T111200",
            "authors": [
                "Matthew Frankel",
                "CFP®"
            ],
            "summary": "These stocks have significantly underperformed the market. But are they really \"cheap\"?",
            "banner_image": "https://g.foolcdn.com/editorial/images/759391/stock-trader-2022-a.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999355"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.135767,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.068355",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.222838",
                    "ticker_sentiment_score": "0.005434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HES",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "-0.049929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.058937",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 No-Brainer Stocks to Buy With $200 Right Now",
            "url": "https://www.fool.com/investing/2023/12/27/3-no-brainer-stocks-to-buy-with-200-right-now/",
            "time_published": "20231227T102100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "A reasonably modest amount of money can go a long way when it's invested in innovation-driven businesses.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759284%2Ftwo-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.167315,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.031654",
                    "ticker_sentiment_score": "0.058472",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TWOH",
                    "relevance_score": "0.031654",
                    "ticker_sentiment_score": "0.104481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063258",
                    "ticker_sentiment_score": "0.28464",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NEE",
                    "relevance_score": "0.094762",
                    "ticker_sentiment_score": "0.107596",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nasdaq Leads Over NYSE in IPO Listings, Drawing Major Tech and Global Firms in 2023 - Nasdaq  ( NASDAQ:NDAQ ) ",
            "url": "https://www.benzinga.com/markets/equities/23/12/36387988/nasdaq-leads-over-nyse-in-ipo-listings-drawing-major-tech-and-global-firms-in-2023",
            "time_published": "20231226T185522",
            "authors": [
                "Nabaparna Bhattacharya"
            ],
            "summary": "Nasdaq, Inc. NDAQ is reportedly poised to outpace the New York Stock Exchange in securing initial public offerings in 2023. This marks the fifth consecutive year where the once-leading NYSE has trailed its competitor, the Wall Street Journal said in a news report.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/nasdaq-photo_by_sergeitokmakov_via_pixabay-.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.299661,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CAVA",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.165337",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.406106",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.406106",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.305953",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIRK",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.165337",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CART",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.305953",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NXT(EXP20091224)",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.209935",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:NXT",
                    "relevance_score": "0.104683",
                    "ticker_sentiment_score": "0.209935",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Shares Of Chip Designer Arm Hit New All-Time High-Outclassing 2023 IPO Peers",
            "url": "https://www.forbes.com/sites/dereksaul/2023/12/26/shares-of-chip-designer-arm-hit-new-all-time-high-outclassing-2023-ipo-peers/",
            "time_published": "20231226T181004",
            "authors": [
                "Derek Saul"
            ],
            "summary": "British chip designer Arm's stock rallied Tuesday to its highest level since it began trading in September, riding the wave of optimism surrounding generative artificial intelligence to a rare win for recent initial public offerings on the stock market.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/650363f9ba57600a5f52cccb/0x0.jpg?format=jpg&crop=2606,1464,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.252902,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.068778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.159621",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIRK",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.068778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.099066",
                    "ticker_sentiment_score": "0.068778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SFTBF",
                    "relevance_score": "0.19661",
                    "ticker_sentiment_score": "0.24203",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Best Stocks To Buy In 2024? 2 Blue Chip Stocks In Focus",
            "url": "https://stockmarket.com/featured/best-stocks-to-buy-in-2024-2-blue-chip-stocks-in-focus-2023-12-26",
            "time_published": "20231226T153938",
            "authors": [
                "Joe Samuel"
            ],
            "summary": "Blue chip stocks refer to shares of large, well-established companies that have a history of steady earnings and dividend payments. These companies typically have ample cash reserves and operate in mature industries.",
            "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2020/09/cost-stock.jpg",
            "source": "StockMarket.com",
            "category_within_source": "n/a",
            "source_domain": "stockmarket.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.272854,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "COST",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "0.324115",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.439786",
                    "ticker_sentiment_score": "0.327503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.153961",
                    "ticker_sentiment_score": "0.273587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.153961",
                    "ticker_sentiment_score": "0.273587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.153961",
                    "ticker_sentiment_score": "0.273587",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Investors Lose $426 Billion On These 8 Giant Losers This Year",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-investors-lose-billions-on-these-giant-losers-this-year-2023/",
            "time_published": "20231226T130000",
            "authors": [
                "MATT KRANTZ",
                "Investor's Business Daily"
            ],
            "summary": "Investors scored big-time on the biggest S&P 500 stocks this year. But those who picked the wrong stocks suffered mightily. Investors lost $462 billion holding just eight stocks dropping the most market value this year, including ailing vaccine maker Pfizer ( PFE ) , struggling oil giant Chevron ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-sadinvestors-03-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.022152,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.212425",
                    "ticker_sentiment_score": "0.074915",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "0.154439",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.212425",
                    "ticker_sentiment_score": "-0.057835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "-0.041371",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.07157",
                    "ticker_sentiment_score": "-0.071879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.07157",
                    "ticker_sentiment_score": "-0.032605",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "0.213747",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.346642",
                    "ticker_sentiment_score": "0.121081",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets",
            "url": "https://www.globenewswire.com/news-release/2023/12/26/2801027/0/en/LianBio-Enters-into-Agreement-Assigning-its-Rights-for-NBTXR3-in-China-and-Other-Asian-Markets.html",
            "time_published": "20231226T070000",
            "authors": [
                "LianBio"
            ],
            "summary": "SHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- LianBio ( Nasdaq: LIAN ) , a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Janssen ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/9f90758c-2af0-42c9-a544-2877edbc0c41",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.230093,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.118842",
                    "ticker_sentiment_score": "0.052819",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LIAN",
                    "relevance_score": "0.545243",
                    "ticker_sentiment_score": "0.370515",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.039745",
                    "ticker_sentiment_score": "0.170952",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets - LianBio  ( NASDAQ:LIAN ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36380995/lianbio-enters-into-agreement-assigning-its-rights-for-nbtxr3-in-china-and-other-asian-markets",
            "time_published": "20231226T070000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "SHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- LianBio LIAN, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Janssen Pharmaceutica ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.227601,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LIAN",
                    "relevance_score": "0.498416",
                    "ticker_sentiment_score": "0.341973",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.1145",
                    "ticker_sentiment_score": "0.052047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.038284",
                    "ticker_sentiment_score": "0.128803",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.038284",
                    "ticker_sentiment_score": "0.160376",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets",
            "url": "https://www.globenewswire.com/news-release/2023/12/26/2801026/0/en/Nanobiotix-Partner-LianBio-Assigns-Its-Development-and-Commercialization-Rights-for-NBTXR3-in-China-and-Other-Asian-Markets.html",
            "time_published": "20231226T070000",
            "authors": [
                "Nanobiotix S.A."
            ],
            "summary": "PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext : NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.156837,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.556946",
                    "ticker_sentiment_score": "0.211697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LIAN",
                    "relevance_score": "0.201803",
                    "ticker_sentiment_score": "0.115515",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.074574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NANO",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.074574",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets - Nanobiotix  ( NASDAQ:NBTX ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36380993/nanobiotix-partner-lianbio-assigns-its-development-and-commercialization-rights-for-nbtxr3-in-chin",
            "time_published": "20231226T070000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- NANOBIOTIX NBTX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has entered into an agreement with ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.152,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.577919",
                    "ticker_sentiment_score": "0.212491",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LIAN",
                    "relevance_score": "0.200134",
                    "ticker_sentiment_score": "0.113182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.033703",
                    "ticker_sentiment_score": "0.074503",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Is The Market Feeling About Johnson & Johnson? - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/short-sellers/23/12/36379602/how-is-the-market-feeling-about-johnson-johnson",
            "time_published": "20231225T173024",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Johnson & Johnson's JNJ short percent of float has risen 12.73% since its last report. The company recently reported that it has 15.00 million shares sold short, which is 0.62% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.265071,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.15378",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Top Dividend Stocks You Can Buy and Hold Forever",
            "url": "https://www.fool.com/investing/2023/12/24/2-top-dividend-stocks-you-can-buy-and-hold-forever/",
            "time_published": "20231224T101200",
            "authors": [
                "Matthew DiLallo"
            ],
            "summary": "These companies pay very durable dividends.",
            "banner_image": "https://g.foolcdn.com/editorial/images/759137/rising-stacks-of-copper-pennies-next-to-a-jar-filled-of-copper-pennies.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.455957,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.364529",
                    "ticker_sentiment_score": "0.494193",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NEE",
                    "relevance_score": "0.265089",
                    "ticker_sentiment_score": "0.38117",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "5 Top Stocks to Buy With Your End-of-the-Year Bonus",
            "url": "https://www.fool.com/investing/2023/12/23/5-top-stocks-to-buy-with-your-bonus/",
            "time_published": "20231223T100000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Your bonus could become the gift that keeps on giving.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758889%2Fgettyimages-1178121483.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999992"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.41286,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.147103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.229872",
                    "ticker_sentiment_score": "0.418924",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.045518",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.116161",
                    "ticker_sentiment_score": "0.275375",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.150159",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Check Out What Whales Are Doing With JNJ - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/markets/options/23/12/36363065/check-out-what-whales-are-doing-with-jnj",
            "time_published": "20231222T150240",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 10 unusual trades. Delving into the details, we found 70% of traders were bullish, while 30% showed bearish tendencies.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.223286,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "0.141264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.07887",
                    "ticker_sentiment_score": "-0.112709",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.677874",
                    "ticker_sentiment_score": "0.370294",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Cosmetic Skin Care Market is Anticipated to Reach USD 154.7 billion at a CAGR of 4.8% CAGR by 2031 - Report by Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36362289/cosmetic-skin-care-market-is-anticipated-to-reach-usd-154-7-billion-at-a-cagr-of-4-8-cagr-by-2031-",
            "time_published": "20231222T143000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Dec. 22, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global cosmetic skin care market is estimated to flourish at a CAGR of 4.8% from 2022 to 2031.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.443568,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "RGBD",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.138446",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSDOF",
                    "relevance_score": "0.141935",
                    "ticker_sentiment_score": "0.331122",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.277012",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICNB",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.285514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.071251",
                    "ticker_sentiment_score": "0.271547",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COTY",
                    "relevance_score": "0.035661",
                    "ticker_sentiment_score": "0.285514",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Surgical Sutures Market is Expected to Reach $5.5 Billion | MarketsandMarkets.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36359974/surgical-sutures-market-is-expected-to-reach-5-5-billion-marketsandmarkets",
            "time_published": "20231222T123000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Chicago, Dec. 22, 2023 ( GLOBE NEWSWIRE ) -- Surgical Sutures market in terms of revenue was estimated to be worth $4.0 Billion in 2023 and is poised to reach $5.5 billion by 2028, growing at a CAGR of 6.4% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.274092,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.046452",
                    "ticker_sentiment_score": "0.060005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.046452",
                    "ticker_sentiment_score": "0.209397",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.046452",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Feminine Hygiene Market size to worth $63.5 billion by 2030, globally at a CAGR of 7.4%, says Coherent Market Insights",
            "url": "https://www.prnewswire.com/news-releases/feminine-hygiene-market-size-to-worth-63-5-billion-by-2030--globally-at-a-cagr-of-7-4-says-coherent-market-insights-302021679.html",
            "time_published": "20231222T091400",
            "authors": [
                "Coherent Market Insights"
            ],
            "summary": "SEATTLE, Dec. 22, 2023 /PRNewswire/ -- As per the recent analysis by Coherent Market Insights, the global feminine hygiene market size was valued at US$ 33.3 billion in 2023 and is predicted to reach US$ 63.5 billion by 2030.",
            "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.319602,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EPC",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.044076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMB",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.044076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ONXXF",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.044076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.044076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NAII",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.072338",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.044076",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma industry optimistic, expects more collaborative efforts in New Year",
            "url": "https://www.business-standard.com/industry/news/pharma-industry-optimistic-expects-more-collaborative-efforts-in-new-year-123122200253_1.html",
            "time_published": "20231222T060249",
            "authors": [
                "Press Trust of India"
            ],
            "summary": "The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/04/full/1701712189-5262.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.33044,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.055751",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.055751",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Monthly Meeting Q&A with Jim Cramer: Stock buying and selling strategies into year end",
            "url": "https://www.cnbc.com/2023/12/21/monthly-meeting-qa-with-jim-cramer-stock-buying-and-selling-strategies-into-year-end.html",
            "time_published": "20231221T180706",
            "authors": [
                "Paulina Likos"
            ],
            "summary": "During the December Monthly Meeting, we took questions directly from Investing Club members.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107204415-1678206782470-Eaton_Corporation-OB-Photo-MW-20230307-0001-PRESS-1.JPG?v=1678381479&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                }
            ],
            "overall_sentiment_score": 0.10348,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HUM",
                    "relevance_score": "0.136666",
                    "ticker_sentiment_score": "0.054069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VMW",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYT",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLB",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.044336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.039224",
                    "ticker_sentiment_score": "0.042455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.117295",
                    "ticker_sentiment_score": "0.050055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.155954",
                    "ticker_sentiment_score": "0.058574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRA",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? - MeiraGTx Hldgs  ( NASDAQ:MGTX ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36343217/why-is-eye-disease-related-gene-therapy-focused-meiragtx-stock-soaring-today",
            "time_published": "20231221T161113",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "MeiraGTx Holdings plc MGTX on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson JNJ company, for the remaining interests in botaretigene sparoparvovec ( bota-vec, formerly AAV-RPGR ) for X-linked retinitis pigmentosa ( XLRP ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/21/mgtx.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.176228,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MGTX",
                    "relevance_score": "0.775204",
                    "ticker_sentiment_score": "0.386666",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.327064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.512093",
                    "ticker_sentiment_score": "0.263384",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Medical Aesthetics Market is Expected to Reach $25.9 Billion | MarketsandMarkets.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36341317/medical-aesthetics-market-is-expected-to-reach-25-9-billion-marketsandmarkets",
            "time_published": "20231221T123000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Chicago, Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- Medical Aesthetics market in terms of revenue was estimated to be worth $15.4 Billion in 2023 and is poised to reach $25.9 billion by 2028, growing at a CAGR of 11.0% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.266215,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.083687",
                    "ticker_sentiment_score": "0.042882",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHC",
                    "relevance_score": "0.083687",
                    "ticker_sentiment_score": "0.135235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INMD",
                    "relevance_score": "0.041901",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.041901",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million - MeiraGTx Hldgs  ( NASDAQ:MGTX ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36340683/meiragtx-announces-asset-purchase-agreement-involving-its-aav-rpgr-collaboration-for-up-to-415-mil",
            "time_published": "20231221T120000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec ( bota-vec, formerly AAV-RPGR ) for the treatment of X-linked retinitis pigmentosa ( XLRP ) for a total of up to $415 million - MeiraGTx to receive $130 million in upfront and near-term milestone ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.142073,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.064914",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MGTX",
                    "relevance_score": "0.405029",
                    "ticker_sentiment_score": "0.269953",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.218785",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.130011",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 No-Brainer Buys During a Stock Market Crash",
            "url": "https://www.fool.com/investing/2023/12/21/2-no-brainer-buys-during-a-stock-market-crash/",
            "time_published": "20231221T115500",
            "authors": [
                "Jeremy Bowman"
            ],
            "summary": "If the stock market pulls back, JPMorgan Chase and Microsoft should be at the top of your buy list.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758856%2Finvesting-screen-analysis-investor-growth-stocks.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.109176,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.409742",
                    "ticker_sentiment_score": "0.062559",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.511256",
                    "ticker_sentiment_score": "-0.00332",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.061315",
                    "ticker_sentiment_score": "-0.06417",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Got $1,000? 5 of the Safest Stocks to Buy for 2024",
            "url": "https://www.fool.com/investing/2023/12/21/got-1000-5-of-the-safest-stocks-to-buy-for-2024/",
            "time_published": "20231221T102100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "Regardless of what's thrown Wall Street's way in the new year, these tried-and-true companies can deliver for their shareholders.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758752%2Fperson-holding-cash-bills-money-hundred-dollar-fifty-dividend-income-invest-retire-spend-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.287339,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "YORW",
                    "relevance_score": "0.120885",
                    "ticker_sentiment_score": "0.14337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.18046",
                    "ticker_sentiment_score": "0.136706",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.090816",
                    "ticker_sentiment_score": "0.101955",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.15078",
                    "ticker_sentiment_score": "0.264171",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.030331",
                    "ticker_sentiment_score": "0.16967",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.030331",
                    "ticker_sentiment_score": "-0.009711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NEE",
                    "relevance_score": "0.18046",
                    "ticker_sentiment_score": "0.125075",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Judge Bars Testimony Linking Kenvue's Pain Killer Tylenol to Autism in Pregnancy - Kenvue  ( NYSE:KVUE ) ",
            "url": "https://www.benzinga.com/news/23/12/36321800/judge-bars-testimony-linking-kenvues-pain-killer-tylenol-to-autism-in-pregnancy",
            "time_published": "20231220T155118",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "U.S. District Judge Denise Cote ruled against allowing expert witnesses to testify that Johnson & Johnson JNJ spin-off Kenvue Inc's KVUE painkiller Tylenol could cause autism in babies if taken during pregnancy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/20/tylenol.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.128573,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.348919",
                    "ticker_sentiment_score": "0.120346",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "-0.099192",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.348919",
                    "ticker_sentiment_score": "-0.069203",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "-0.099192",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "-0.099192",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Oral Care Market Size is Estimated to Reach USD 56.91 billion by 2030, Growing at a CAGR of 6.1%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36324134/global-oral-care-market-size-is-estimated-to-reach-usd-56-91-billion-by-2030-growing-at-a-cagr-of-",
            "time_published": "20231220T135000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, Dec. 20, 2023 ( GLOBE NEWSWIRE ) -- Oral hygiene is the process of maintaining a healthy, disease-free mouth. Regular dental exams that include cleanings, exams, X-rays, tooth brushing, and flossing are required for excellent oral hygiene.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.185143,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.097259",
                    "ticker_sentiment_score": "0.120816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.097259",
                    "ticker_sentiment_score": "0.178887",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.13197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HENKY",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.13197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CL",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.13197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LIOPF",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.13197",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Martin Glensbjerg takes up new position at ChemoMetec",
            "url": "https://www.globenewswire.com/news-release/2023/12/20/2799277/0/en/Martin-Glensbjerg-takes-up-new-position-at-ChemoMetec.html",
            "time_published": "20231220T133500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.237334,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.042426",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.042426",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.042426",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma",
            "url": "https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html",
            "time_published": "20231220T120001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107347356-1702499004188-gettyimages-1839792823-roy-notitle231211_np5rX.jpeg?v=1702499083&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                }
            ],
            "overall_sentiment_score": 0.016958,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "0.045817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.08091",
                    "ticker_sentiment_score": "-0.013704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "-0.015961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.027011",
                    "ticker_sentiment_score": "0.172126",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "-0.091089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.068154",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.08091",
                    "ticker_sentiment_score": "0.132047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.08091",
                    "ticker_sentiment_score": "0.05643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "-0.015961",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2200357/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now",
            "time_published": "20231220T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default103.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.319158,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.044463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.044463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.044463",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Goldman Sachs is considering a sweeping overhaul of its management committee. Here's what executives are thinking.",
            "url": "https://www.businessinsider.com/goldman-sachs-management-committee-david-solomon-and-john-waldron-2023-12",
            "time_published": "20231219T213900",
            "authors": [
                "Dakin Campbell"
            ],
            "summary": "What a Goldman Sachs Overhaul Could Mean for David Solomon and John Waldron. - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.10292,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.070621",
                    "ticker_sentiment_score": "0.049197",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASBRF",
                    "relevance_score": "0.035345",
                    "ticker_sentiment_score": "0.083802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035345",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bioventus Names Robert Claypoole as President and Chief Executive Officer",
            "url": "https://www.globenewswire.com/news-release/2023/12/19/2798909/0/en/Bioventus-Names-Robert-Claypoole-as-President-and-Chief-Executive-Officer.html",
            "time_published": "20231219T213000",
            "authors": [
                "Bioventus",
                "Inc."
            ],
            "summary": "Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/e10db184-593a-40b5-af02-627c27583108",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.310096,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.088581",
                    "ticker_sentiment_score": "0.119224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BVS",
                    "relevance_score": "0.495541",
                    "ticker_sentiment_score": "0.467027",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.029581",
                    "ticker_sentiment_score": "0.202708",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bioventus Names Robert Claypoole as President and Chief Executive Officer - Bioventus  ( NASDAQ:BVS ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36315192/bioventus-names-robert-claypoole-as-president-and-chief-executive-officer",
            "time_published": "20231219T213000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "DURHAM, N.C., Dec. 19, 2023 ( GLOBE NEWSWIRE ) -- Bioventus Inc. BVS ( \"Bioventus\" or the \"Company\" ) , a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert ( Rob ) Claypoole as Bioventus' President and Chief Executive Officer and a ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.307685,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.087291",
                    "ticker_sentiment_score": "0.118789",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BVS",
                    "relevance_score": "0.51249",
                    "ticker_sentiment_score": "0.469807",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.029149",
                    "ticker_sentiment_score": "0.202448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Penny Stocks Under $3 To Watch Right Now",
            "url": "https://pennystocks.com/featured/2023/12/19/3-penny-stocks-under-3-to-watch-right-now-december-2023/",
            "time_published": "20231219T192211",
            "authors": [
                "J. Phillip"
            ],
            "summary": "As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk. This guide explores the fundamentals of penny stocks, how announcements drive explosive moves, and resources to ...",
            "banner_image": "https://pennystocks.com/wp-content/uploads/2023/03/3-penny-stocks-to-buy-watch-hold-this-week-now.jpg",
            "source": "PennyStocks.com",
            "category_within_source": "n/a",
            "source_domain": "pennystocks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.221107,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.03157",
                    "ticker_sentiment_score": "0.070069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.03157",
                    "ticker_sentiment_score": "-0.045528",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LUNG",
                    "relevance_score": "0.03157",
                    "ticker_sentiment_score": "-0.045528",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HNST",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.272163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.122282",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NRXP",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.048505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AUVI",
                    "relevance_score": "0.156868",
                    "ticker_sentiment_score": "0.20638",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.03157",
                    "ticker_sentiment_score": "0.139227",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Kenvue's stock rises after favorable court ruling in Tylenol litigation",
            "url": "https://www.marketwatch.com/story/kenvue-shares-rise-after-favorable-court-ruling-in-tylenol-litigation-3daa0865",
            "time_published": "20231219T164300",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Kenvue shares gained nearly 5% Tuesday morning after a federal court's ruling in a product-liability case appeared to work in the Tylenol maker's favor.",
            "banner_image": "https://images.mktw.net/im-773280/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.102927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.496597",
                    "ticker_sentiment_score": "0.289172",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.241898",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.176502",
                    "ticker_sentiment_score": "-0.122694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.176502",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.241898",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Migraine Market Size Is Expected To Reach $2.15 Billion By 2028 At A CAGR Of 2.8% As Per The Business Research Company's Migraine Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36308373/the-migraine-market-size-is-expected-to-reach-2-15-billion-by-2028-at-a-cagr-of-2-8-as-per-the-bus",
            "time_published": "20231219T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Dec. 19, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Migraine Global Market Report 2024, the migraine market has demonstrated a steady growth trajectory, marking an increase from $1.87 billion in 2023 to an estimated $1.93 billion in 2024.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.273413,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "-0.006038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "-0.006038",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Healthcare Stocks That Could Help Make You a Millionaire",
            "url": "https://www.fool.com/investing/2023/12/19/3-healthcare-stocks-could-help-make-you-rich/",
            "time_published": "20231219T100000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "These stocks each have reached an important turning point that could signal growth ahead.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758604%2Fgettyimages-474008420.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.295687,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.05339",
                    "ticker_sentiment_score": "0.294926",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.159218",
                    "ticker_sentiment_score": "0.23199",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TDOC",
                    "relevance_score": "0.159218",
                    "ticker_sentiment_score": "0.106569",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Face Wash Market to grow by USD 8.38 billion from 2023 to 2028 | Market is fragmented due to the presence of ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/face-wash-market-to-grow-by-usd-8-38-billion-from-2023-to-2028--market-is-fragmented-due-to-the-presence-of-prominent-companies-like-alchemee-llc-amway-corp-and-beiersdorf-ag-and-many-more---technavio-302018052.html",
            "time_published": "20231219T071500",
            "authors": [],
            "summary": "Face Wash Market to grow by USD 8.38 billion from 2023 to 2028 | Market is fragmented due to the presence of ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.251021,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BDRFF",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHDRF",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KAOCF",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SSDOF",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HNST",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.048919",
                    "ticker_sentiment_score": "0.060598",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Increases Yet Falls Behind Market: What Investors Need to Know",
            "url": "https://www.zacks.com/stock/news/2199619/johnson-johnson-jnj-increases-yet-falls-behind-market-what-investors-need-to-know",
            "time_published": "20231218T224519",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $155.44, marking a +0.18% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default141.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99246"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.14675,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.554916",
                    "ticker_sentiment_score": "0.208639",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Schizophrenia Future Outlook 2024-2028: Forecasted Market Rate, Growth Factors, And Leading Segments As Per The Business Research Company's Schizophrenia Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36286286/schizophrenia-future-outlook-2024-2028-forecasted-market-rate-growth-factors-and-leading-segments-",
            "time_published": "20231218T163000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Schizophrenia Global Market Report 2024, the schizophrenia market has exhibited robust growth, surging from $5.48 billion in 2023 to $5.82 billion in 2024, reflecting a notable compound annual growth rate ( CAGR ) ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.275536,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.153093",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.252095",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.153093",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.153093",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "UNICEF USA BrandVoice: Closing The Health Inequity Gap By Investing In Data And Technology",
            "url": "https://www.forbes.com/sites/unicefusa/2023/12/18/closing-the-health-inequity-gap-by-investing-in-data-and-technology/",
            "time_published": "20231218T153800",
            "authors": [
                "Cynthia Tully"
            ],
            "summary": "Closing The Health Inequity Gap By Investing In Data And Technology Forbes ...",
            "banner_image": "https://blogs-images.forbes.com/assets/images/avatars/blog-4819_400_bef01cc80e5554bcfe107d356a75ae6c.jpg",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.382287,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CYH",
                    "relevance_score": "0.093775",
                    "ticker_sentiment_score": "0.205906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.031322",
                    "ticker_sentiment_score": "0.22609",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Makeup Remover Market Size to be Worth USD 4.3 billion by 2031, with Grow at CAGR of 6.5%| Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36279593/makeup-remover-market-size-to-be-worth-usd-4-3-billion-by-2031-with-grow-at-cagr-of-6-5-transparen",
            "time_published": "20231218T123000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The makeup remover market was valued at over US$ 2.3 billion in 2021. A CAGR of 6.5% is expected between 2022 and 2031. The makeup remover sales are expected to exceed US$ 4.3 billion by ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.32146,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.033421",
                    "ticker_sentiment_score": "-0.095627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.033421",
                    "ticker_sentiment_score": "-0.095627",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Muckle Wells Syndrome Market to Reach US$ 335.9 Million by 2030, Rising at a CAGR of 12.6% | Report by CoherentMI",
            "url": "https://www.prnewswire.com/news-releases/muckle-wells-syndrome-market-to-reach-us-335-9-million-by-2030--rising-at-a-cagr-of-12-6--report-by-coherentmi-302017763.html",
            "time_published": "20231218T115400",
            "authors": [
                "Coherent Market Insights"
            ],
            "summary": "BURLINGAME, Calif., Dec. 18, 2023 /PRNewswire/ -- CoherentMI published a report, titled, Muckle Wells Syndrome Market is estimated to value at US$ 146.4 Million in the year 2023 and is anticipated to reach US$ 335.9 Million by 2030, at a CAGR of 12.6% during forecast period 2023-2030.",
            "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.280832,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.030331",
                    "ticker_sentiment_score": "0.083206",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.030331",
                    "ticker_sentiment_score": "0.083206",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.030331",
                    "ticker_sentiment_score": "0.083206",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP",
            "url": "https://www.zacks.com/stock/news/2199138/the-zacks-analyst-blog-highlights-jpmorgan-chase-abbott-laboratories-qualcomm-johnson-johnson-and-bhp",
            "time_published": "20231218T100900",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ae/82.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.205432,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.186259",
                    "ticker_sentiment_score": "0.048224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHP",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.037836",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.305437",
                    "ticker_sentiment_score": "0.310973",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.246582",
                    "ticker_sentiment_score": "0.175741",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.037836",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/viatris-continues-its-preparations-for-phase-2-of-its-strategic-plan-by-announcing-the-appointment-of-theodora-doretta-mistras-as-chief-financial-officer-effective-march-1-2024-and-philippe-martin-as-chief-rd-officer-302017098.html",
            "time_published": "20231215T214500",
            "authors": [],
            "summary": "Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.306959,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.024852",
                    "ticker_sentiment_score": "0.063478",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.024852",
                    "ticker_sentiment_score": "0.070321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.07446",
                    "ticker_sentiment_score": "0.243721",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.024852",
                    "ticker_sentiment_score": "0.07612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.696068",
                    "ticker_sentiment_score": "0.48508",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MG",
                    "relevance_score": "0.12378",
                    "ticker_sentiment_score": "0.187159",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.024852",
                    "ticker_sentiment_score": "0.070321",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Boycotts and protests - how are people around the world defying Israel?",
            "url": "https://www.aljazeera.com/news/2023/12/15/boycotts-and-protests-how-are-people-around-the-world-defying-israel",
            "time_published": "20231215T201705",
            "authors": [
                "Delaney Nolan",
                "Marium Ali",
                "Alia Chughtai"
            ],
            "summary": "Al Jazeera takes a look at the movements against Israel and illegal settlements in Palestine. From Jakarta to San Francisco, hundreds of thousands of people have taken to the streets over the past two months to protest Israel's ongoing assault on Gaza, which has killed more than 18,700 people, ...",
            "banner_image": "https://www.aljazeera.com/wp-content/uploads/2023/12/Interactive_Boycott_movement_4-10-1702628484.jpg?w=770&resize=770%2C770",
            "source": "Al Jareeza",
            "category_within_source": "n/a",
            "source_domain": "www.aljazeera.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": -0.021785,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.073886",
                    "ticker_sentiment_score": "0.017318",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PZZA",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "-0.063011",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.036983",
                    "ticker_sentiment_score": "0.064967",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPRI",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.018496",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dow Jones Holds Near Highs As Boeing Stock Jumps; DocuSign Surges On Takeover Chatter",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-holds-near-highs-boeing-stock-jumps-docusign-surges-takeover-chatter/",
            "time_published": "20231215T201400",
            "authors": [
                "KEN SHREVE",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Holds Near Highs As Boeing Stock Jumps. DocuSign Surges On Takeover Chatter Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.195198,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.28305",
                    "ticker_sentiment_score": "0.515453",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.295365",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.15783",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.15783",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.15783",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.389327",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.367561",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LEN",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "0.103081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "0.27171",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.292898",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.295365",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DOCU",
                    "relevance_score": "0.143843",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.214304",
                    "ticker_sentiment_score": "0.245219",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial",
            "url": "https://www.benzinga.com/node/36256704",
            "time_published": "20231215T155843",
            "authors": [
                "",
                "S",
                "g",
                "d",
                "a",
                "n",
                "h",
                "i",
                "V"
            ],
            "summary": "AC Immune SA's ( NASDAQ: ACIU ) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 ( JNJ-64042056 ) in patients with preclinical Alzheimer's disease ( AD ) , those individuals not yet showing symptoms.",
            "banner_image": "https://cdn.benzinga.com/files/imagecache/story_image_685x375C/images/story/2023/12/15/aciu.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.101153,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ACIU",
                    "relevance_score": "0.619618",
                    "ticker_sentiment_score": "0.190065",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.165157",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Cartilage Repair / Cartilage Regeneration Market Worth $2.8 billion | MarketsandMarkets",
            "url": "https://www.prnewswire.com/news-releases/cartilage-repair--cartilage-regeneration-market-worth-2-8-billion--marketsandmarkets-302016408.html",
            "time_published": "20231215T153000",
            "authors": [
                "MarketsandMarkets"
            ],
            "summary": "CHICAGO, Dec. 15, 2023 /PRNewswire/ -- Cartilage Repair / Cartilage Regeneration Market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $2.8 billion by 2028, growing at a CAGR of 17.2% from 2023 to 2028 according to a new report by MarketsandMarkets.",
            "banner_image": "https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.280453,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ANIK",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "-0.011354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZBH",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "-0.011354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "-0.011354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "-0.011354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VCEL",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "-0.011354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNMD",
                    "relevance_score": "0.033098",
                    "ticker_sentiment_score": "-0.011354",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial - AC Immune  ( NASDAQ:ACIU ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36255065/ac-immunes-targeted-anti-ptau-active-immunotherapy-for-alzheimers-disease-advances-into-phase-2b-t",
            "time_published": "20231215T122247",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Potentially registration-enabling Phase 2b study ( ReTain ) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease ( AD )",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.133632,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ACIU",
                    "relevance_score": "0.310843",
                    "ticker_sentiment_score": "0.156537",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.050182",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial",
            "url": "https://www.globenewswire.com/news-release/2023/12/15/2796982/0/en/AC-Immune-s-Targeted-Anti-pTau-Active-Immunotherapy-for-Alzheimer-s-Disease-Advances-into-Phase-2b-Trial.html",
            "time_published": "20231215T122200",
            "authors": [
                "AC Immune SA"
            ],
            "summary": "• Potentially registration-enabling Phase 2b study ( ReTain ) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease ( AD ) • Anti-pTau active immunotherapy being designed to potentially prevent or reduce ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/0065cdfd-b9fc-4994-8aca-731c1d031b51",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.138392,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ACIU",
                    "relevance_score": "0.291707",
                    "ticker_sentiment_score": "0.144885",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "0.050176",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is SPDR S&P Pharmaceuticals ETF  ( XPH )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2198396/is-spdr-sp-pharmaceuticals-etf-xph-a-strong-etf-right-now",
            "time_published": "20231215T112003",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default94.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999953"
                }
            ],
            "overall_sentiment_score": 0.208864,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "0.053966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.05654",
                    "ticker_sentiment_score": "0.065917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "0.053966",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.112797",
                    "ticker_sentiment_score": "0.053966",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Decade of Excellence: HR Asia Best Companies to Work for in Asia Celebrates 10th Anniversary with Recognition of 78 Outstanding Workplaces",
            "url": "https://www.prnewswire.com/apac/news-releases/decade-of-excellence-hr-asia-best-companies-to-work-for-in-asia-celebrates-10th-anniversary-with-recognition-of-78-outstanding-workplaces-302016279.html",
            "time_published": "20231215T035200",
            "authors": [
                "Business Media International"
            ],
            "summary": "Decade of Excellence: HR Asia Best Companies to Work for in Asia Celebrates 10th Anniversary with Recognition of ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2300989/Congratulations_to_the_Winners_of_2023_Malaysia_HR_Asia_Best_Companies_to_Work_in_Asia.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.631776,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DRVN",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.258594",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GEHDY",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.24308",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.24308",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MYTEF",
                    "relevance_score": "0.059488",
                    "ticker_sentiment_score": "0.24308",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html",
            "time_published": "20231214T221500",
            "authors": [],
            "summary": "Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.177123,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALPMF",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ENDPQ",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTGN",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "-0.22385",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.078099",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Integra  ( IART )  to Advance ENT Division With New Buyout Deal",
            "url": "https://www.zacks.com/stock/news/2198095/integra-iart-to-advance-ent-division-with-new-buyout-deal",
            "time_published": "20231214T161400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.993781"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.28448,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IART",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.070167",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.057569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HAE",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.09553",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.057569",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053153",
                    "ticker_sentiment_score": "0.064716",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors",
            "url": "https://www.globenewswire.com/news-release/2023/12/14/2796105/0/en/Beam-Therapeutics-Appoints-Biotech-Executive-Christi-Shaw-to-its-Board-of-Directors.html",
            "time_published": "20231214T113000",
            "authors": [
                "Beam Therapeutics"
            ],
            "summary": "CAMBRIDGE, Mass., Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- ( Nasdaq: BEAM ) , a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors.",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/03af3276-c254-436a-b40d-2ad9a1025f95",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.149411,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.160365",
                    "ticker_sentiment_score": "0.160003",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVTR",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.015373",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.015373",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors - Beam Therapeutics  ( NASDAQ:BEAM ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36232869/beam-therapeutics-appoints-biotech-executive-christi-shaw-to-its-board-of-directors",
            "time_published": "20231214T113000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "CAMBRIDGE, Mass., Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.146976,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.157483",
                    "ticker_sentiment_score": "0.155402",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVTR",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.014369",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.039614",
                    "ticker_sentiment_score": "0.014369",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the SPDR S&P Pharmaceuticals ETF  ( XPH ) ?",
            "url": "https://www.zacks.com/stock/news/2197719/should-you-invest-in-the-spdr-sp-pharmaceuticals-etf-xph",
            "time_published": "20231214T112002",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default309.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.112693,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.059923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.031004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTLT",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.059923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.059923",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Voting Rights and Shares Capital of the Company",
            "url": "https://www.globenewswire.com/news-release/2023/12/13/2795880/0/en/Voting-Rights-and-Shares-Capital-of-the-Company.html",
            "time_published": "20231213T211500",
            "authors": [
                "Nanobiotix S.A."
            ],
            "summary": "In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority ( Autorité des Marchés Financiers ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.183279,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.529185",
                    "ticker_sentiment_score": "0.212059",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "0.165483",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly will be the first trillion-dollar drug company in history, billionaire investor Ken Langone says",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-diabetes-ozempic-wegovy-weight-loss-drug-pharma-2023-12",
            "time_published": "20231213T174000",
            "authors": [
                "Aruni Soni"
            ],
            "summary": "Eli Lilly Will Be the First Trillion-Dollar Drug Company: Ken Langone - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.144091,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HD",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.146535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "-0.108254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "-0.142072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.100148",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Neurosurgery Focused Integra LifeSciences Bolsters Its ENT Portfolio With $275M Acquisition Deal - Integra Lifesciences  ( NASDAQ:IART ) ",
            "url": "https://www.benzinga.com/m-a/23/12/36216015/neurosurgery-focused-integra-lifesciences-bolsters-its-ent-portfolio-with-275m-acquisition-deal",
            "time_published": "20231213T162041",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Integra LifeSciences Holdings Corporation IART agreed to acquire Acclarent Inc. from Ethicon Inc, a Johnson & Johnson JNJ MedTech company, for $275 million in cash, and an additional $5 million upon the achievement of certain regulatory milestones. Acclarent offers medical devices for ENT ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/iart.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.139481,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IART",
                    "relevance_score": "0.481177",
                    "ticker_sentiment_score": "0.322236",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.252987",
                    "ticker_sentiment_score": "0.322612",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pfizer Stock Sinks To 10-Year Low-Why Investors Have Soured On Covid-Era Giant",
            "url": "https://www.forbes.com/sites/dereksaul/2023/12/13/pfizer-stock-sinks-to-10-year-low-why-investors-have-soured-on-covid-era-giant/",
            "time_published": "20231213T143823",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Pfizer stock's struggles continued Wednesday, as shares of the healthcare titan dropped to their lowest level since before the Covid-19 pandemic, the latest dubious milestone for the battered stock that has failed to convert its vaccine boom into long-term sales growth.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6579be819e8d6dd237334ba2/0x0.jpg?format=jpg&crop=1701,1134,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.002458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "0.051337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.033284",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.033284",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.66906",
                    "ticker_sentiment_score": "0.003816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.033284",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
            "url": "https://www.zacks.com/stock/news/2197256/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
            "time_published": "20231213T140011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.215175,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.474082",
                    "ticker_sentiment_score": "0.168058",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "D.R. Horton To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday - Coherent  ( NYSE:COHR ) , C4 Therapeutics  ( NASDAQ:CCCC ) ",
            "url": "https://www.benzinga.com/news/23/12/36213882/d-r-horton-to-rally-around-19-here-are-10-top-analyst-forecasts-for-wednesday",
            "time_published": "20231213T124422",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James cut Nokia Oyj NOK price target from $4.5 to $4.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/d.r._horton_-_logo.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.723405"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.166801,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LULU",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.22508",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.144928",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "-0.078922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.108634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "0.02314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "-0.106392",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRI",
                    "relevance_score": "0.163354",
                    "ticker_sentiment_score": "-0.109528",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOK",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.240404",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "QTWO",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.179906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CCCC",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.215405",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCAT",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.145996",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®",
            "url": "https://www.globenewswire.com/news-release/2023/12/13/2795373/1063/en/Integra-LifeSciences-Announces-Definitive-Agreement-to-Acquire-Acclarent.html",
            "time_published": "20231213T111500",
            "authors": [
                "Integra LifeSciences Holdings Corporation"
            ],
            "summary": "PRINCETON, N.J., Dec. 13, 2023 ( GLOBE NEWSWIRE ) -- Integra LifeSciences Holdings Corporation ( Nasdaq: IART ) , a global leader in medical technology, today announced that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/7bd0384d-f0f2-482e-9fd7-14487b06b349",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.260728,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.129185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IART",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.191018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.099247",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent® - Integra Lifesciences  ( NASDAQ:IART ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36212513/integra-lifesciences-announces-definitive-agreement-to-acquire-acclarent",
            "time_published": "20231213T111500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "The acquisition will become part of Integra's Codman Specialty Surgical ( CSS ) division. The ear, nose and throat ( ENT ) category is a key area of strategic interest and highly complementary to the neurosurgery segment.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Mergers",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.119441,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.121256",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IART",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "0.167399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.090773",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Got $4,000? These 4 Dividend Stocks Could Turn It Into Nearly $200 of Annual Income in 2024.",
            "url": "https://www.fool.com/investing/2023/12/13/got-4000-these-4-dividend-stocks-could-turn-it-int/",
            "time_published": "20231213T104200",
            "authors": [
                "Matthew DiLallo"
            ],
            "summary": "These companies can boost your investment income next year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758028/a-small-chalk-board-with-passive-income-written-out-in-near-stacks-of-100-bills.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.426633,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.227432",
                    "ticker_sentiment_score": "0.322371",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "STAG",
                    "relevance_score": "0.227432",
                    "ticker_sentiment_score": "0.320855",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BEP",
                    "relevance_score": "0.227432",
                    "ticker_sentiment_score": "0.363885",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "KMI",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.370672",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.046095",
                    "ticker_sentiment_score": "0.128388",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period  ( 2019-2032 ) , Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda",
            "url": "https://www.prnewswire.com/news-releases/chronic-inflammatory-demyelinating-polyneuropathy-market-to-register-positive-growth-during-the-study-period-20192032-evaluates-delveinsight--key-companies-to-watch-out---octapharma-argenx-immunovant-sciences-sanofi-janss-302013061.html",
            "time_published": "20231212T220100",
            "authors": [
                "LLP",
                "DelveInsight Business Research"
            ],
            "summary": "Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period ( 2019 ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.07309,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IMVT",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.003097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CABA",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.033781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RLYB",
                    "relevance_score": "0.026241",
                    "ticker_sentiment_score": "0.027812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.026241",
                    "ticker_sentiment_score": "-0.057694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNAC",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.033781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIOAF",
                    "relevance_score": "0.026241",
                    "ticker_sentiment_score": "-0.057694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.015001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPRX",
                    "relevance_score": "0.052455",
                    "ticker_sentiment_score": "0.033781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.026241",
                    "ticker_sentiment_score": "0.027812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UCBJF",
                    "relevance_score": "0.026241",
                    "ticker_sentiment_score": "-0.057694",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGMF",
                    "relevance_score": "0.026241",
                    "ticker_sentiment_score": "0.027812",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.078611",
                    "ticker_sentiment_score": "0.003095",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration",
            "url": "https://www.newswire.ca/news-releases/innocan-pharma-announces-expert-team-for-lpt-cbd-application-to-united-states-food-and-drug-administration-847008069.html",
            "time_published": "20231212T210000",
            "authors": [
                "Innocan Pharma Corporation"
            ],
            "summary": "HERZLIYA, Israel and CALGARY, Alberta, Dec. 12, 2023 /CNW/ -- Innocan Pharma Corporation ( CSE: INNO ) ( FSE: IP4 ) ( OTCQB: INNPF ) ( the \"Company\" or \"Innocan\" ) a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce establishment of a specialized team to prepare ...",
            "banner_image": "https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg?p=facebook",
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.141748,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.034087",
                    "ticker_sentiment_score": "-0.000951",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Unusual Options Activity - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/markets/options/23/12/36202302/johnson-johnson-unusual-options-activity",
            "time_published": "20231212T171617",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Investors with a lot of money to spend have taken a bullish stance on Johnson & Johnson JNJ. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.183085,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.070517",
                    "ticker_sentiment_score": "0.139782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.574235",
                    "ticker_sentiment_score": "0.403269",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "LAZA MEDICAL, INC., A SHIFAMED PORTFOLIO COMPANY, CLOSES $36M IN SERIES A FINANCING",
            "url": "https://www.prnewswire.com/news-releases/laza-medical-inc-a-shifamed-portfolio-company-closes-36m-in-series-a-financing-302012751.html",
            "time_published": "20231212T141000",
            "authors": [
                "Inc.",
                "Laza Medical"
            ],
            "summary": "Company accelerates development of its AI-powered robotically-assisted imaging solution for cardiovascular interventions and appoints seasoned medtech executive as General Manager LOS GATOS, Calif., Dec. 12, 2023 /PRNewswire/ -- , the latest portfolio company, announced today that it has closed ...",
            "banner_image": "https://mma.prnewswire.com/media/2298393/Laza_Logo_TM_RGB_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.4636,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "-0.018141",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.213674",
                    "ticker_sentiment_score": "-0.029686",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
            "url": "https://www.zacks.com/stock/news/2196537/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
            "time_published": "20231212T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Style Box ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.242769,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.061315",
                    "ticker_sentiment_score": "0.117018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.194742",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CVX",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.068311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.068311",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.068311",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Vanguard High Dividend Yield ETF  ( VYM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2196547/is-vanguard-high-dividend-yield-etf-vym-a-strong-etf-right-now",
            "time_published": "20231212T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default238.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.29333,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "0.060376",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "0.060376",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "0.060376",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Outpaces Stock Market Gains: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2196431/johnson-johnson-jnj-outpaces-stock-market-gains-what-you-should-know",
            "time_published": "20231211T224518",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) closed at $155.06 in the latest trading session, marking a +0.41% move from the prior day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default127.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.264619,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.462395",
                    "ticker_sentiment_score": "0.34181",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say - Arcellx  ( NASDAQ:ACLX ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36181675/blood-cancer-player-arcellxs-lead-product-exceeds-expectations-analysts-say",
            "time_published": "20231211T193358",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Friday, Arcellx Inc ACLX announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel ( anito-cel ) for relapsed and/or refractory multiple myeloma. The interim anito-cel Phase 1 clinical results ( October 15, 2023 cutoff date ) demonstrate deep ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/11/aclx.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.151109,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ACLX",
                    "relevance_score": "0.359014",
                    "ticker_sentiment_score": "0.125427",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.244109",
                    "ticker_sentiment_score": "0.103098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LEGN",
                    "relevance_score": "0.244109",
                    "ticker_sentiment_score": "0.103098",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions - Gilead Sciences  ( NASDAQ:GILD ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36179349/gilead-sciences-battles-rising-threat-of-drug-counterfeiting-initiates-legal-actions",
            "time_published": "20231211T171151",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Gilead Sciences Inc GILD faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion in counterfeit drugs annually.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/11/gilead.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": -0.061031,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GILD",
                    "relevance_score": "0.375251",
                    "ticker_sentiment_score": "-0.274068",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.375251",
                    "ticker_sentiment_score": "0.36812",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Fraud in a bottle: How Big Pharma takes on criminals who make millions off counterfeit drugs",
            "url": "https://www.cnbc.com/2023/12/11/fraud-in-a-bottle-big-pharma-takes-on-counterfeit-drugs.html",
            "time_published": "20231211T140001",
            "authors": [
                "Contessa Brewer",
                "Scott Zamost"
            ],
            "summary": "A CNBC investigation found criminal networks altering pill bottles of lifesaving drugs and then selling them back to pharmacies at large discounts.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107345437-1702070982673-1702064178880-PILL_FRAUD_FINAL_12_8_YOU_TUBE_R1.jpg?v=1702070985&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.009621,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GILD",
                    "relevance_score": "0.018243",
                    "ticker_sentiment_score": "-0.078369",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.05469",
                    "ticker_sentiment_score": "-0.068818",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors",
            "url": "https://www.globenewswire.com/news-release/2023/12/11/2793894/0/en/The-Honest-Company-Announces-Appointment-of-Michael-Barkley-Alissa-Hsu-Lynch-and-Andrea-Turner-to-the-Board-of-Directors.html",
            "time_published": "20231211T140000",
            "authors": [
                "Inc.",
                "The Honest Company"
            ],
            "summary": "LOS ANGELES, Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- The Honest Company ( NASDAQ: HNST ) , a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/065a59e7-479f-41f7-9d27-77df89ac7df7",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.36923,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GIS",
                    "relevance_score": "0.041394",
                    "ticker_sentiment_score": "0.112466",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.188664",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LUNG",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.092823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HNST",
                    "relevance_score": "0.283635",
                    "ticker_sentiment_score": "0.558704",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.21644",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors - Pulmonx  ( NASDAQ:LUNG ) , Honest Co  ( NASDAQ:HNST ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36176162/the-honest-company-announces-appointment-of-michael-barkley-alissa-hsu-lynch-and-andrea-turner-to-",
            "time_published": "20231211T140000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LOS ANGELES, Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- The Honest Company HNST, a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.366992,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GIS",
                    "relevance_score": "0.040969",
                    "ticker_sentiment_score": "0.112406",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.08183",
                    "ticker_sentiment_score": "0.185179",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LUNG",
                    "relevance_score": "0.08183",
                    "ticker_sentiment_score": "0.092659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HNST",
                    "relevance_score": "0.280846",
                    "ticker_sentiment_score": "0.552244",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.08183",
                    "ticker_sentiment_score": "0.216068",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the iShares U.S. Pharmaceuticals ETF  ( IHE ) ?",
            "url": "https://www.zacks.com/stock/news/2195941/should-you-invest-in-the-ishares-us-pharmaceuticals-etf-ihe",
            "time_published": "20231211T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default127.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.163989,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.067158",
                    "ticker_sentiment_score": "0.032048",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.061752",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.043607",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.061752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
            "url": "https://www.zacks.com/stock/news/2195947/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
            "time_published": "20231211T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.310406,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.049945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.049945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.049945",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 Top Dividend Stocks to Buy Now",
            "url": "https://www.fool.com/investing/2023/12/11/2-top-dividend-stocks-to-buy-now/",
            "time_published": "20231211T103000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "You can snap up these particular dividend stocks for a bargain today.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757779%2Finvestor-drinks-coffee.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.988787"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.383216,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KO",
                    "relevance_score": "0.52706",
                    "ticker_sentiment_score": "0.472949",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.057215",
                    "ticker_sentiment_score": "0.284024",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.163578",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "5 Phenomenal Stocks in Warren Buffett's \"Secret\" Portfolio That Are Screaming Buys in 2024",
            "url": "https://www.fool.com/investing/2023/12/11/5-stocks-warren-buffett-secret-portfolio-buy-2024/",
            "time_published": "20231211T100600",
            "authors": [
                "Sean Williams"
            ],
            "summary": "The Oracle of Omaha's $610 million hidden portfolio has five amazing bargains hiding in plain sight.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757167%2Fstopwatch-time-to-buy-stock-market-correction-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.212334,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PYPL",
                    "relevance_score": "0.081092",
                    "ticker_sentiment_score": "0.084828",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.187775",
                    "ticker_sentiment_score": "0.20182",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.128797",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.134741",
                    "ticker_sentiment_score": "0.085971",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBAY",
                    "relevance_score": "0.027072",
                    "ticker_sentiment_score": "0.030866",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.081092",
                    "ticker_sentiment_score": "0.146905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.134741",
                    "ticker_sentiment_score": "0.132546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.027072",
                    "ticker_sentiment_score": "0.129708",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Dividend Stocks You Can Safely Hold for Decades",
            "url": "https://www.fool.com/investing/2023/12/09/3-dividend-stocks-you-can-safely-hold-for-decades/",
            "time_published": "20231209T105100",
            "authors": [
                "Keith Speights"
            ],
            "summary": "These companies and their dividends are built to last.",
            "banner_image": "https://g.foolcdn.com/editorial/images/757437/young-woman-smiling-hands-behind-head.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.118585,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.24847",
                    "ticker_sentiment_score": "0.064192",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.473427",
                    "ticker_sentiment_score": "0.194612",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICNB",
                    "relevance_score": "0.063091",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.420483",
                    "ticker_sentiment_score": "0.236448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.040278",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'s 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Johnson & Johnson  ( NYSE:JNJ ) , Altimmune  ( NASDAQ:ALT ) ",
            "url": "https://www.benzinga.com/top-stories/23/12/36157420/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet",
            "time_published": "20231208T175015",
            "authors": [
                "Chris Katje"
            ],
            "summary": "Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/BZ-Stock-Whisper-Index-Logo-6.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.203821,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SATL",
                    "relevance_score": "0.317254",
                    "ticker_sentiment_score": "0.23499",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MLGO",
                    "relevance_score": "0.193723",
                    "ticker_sentiment_score": "0.209573",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.256314",
                    "ticker_sentiment_score": "0.219978",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.193723",
                    "ticker_sentiment_score": "0.092631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.256314",
                    "ticker_sentiment_score": "0.115474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.256314",
                    "ticker_sentiment_score": "0.047362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.029265",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "UPenn President Liz Magill under fire over antisemitism on campus: Jon Huntsman calls her resignation 'not even debatable' | Business",
            "url": "https://www.cnn.com/2023/12/08/business/upenn-president-liz-magill-resign/index.html",
            "time_published": "20231208T131200",
            "authors": [
                "Matt Egan"
            ],
            "summary": "UPenn President Liz Magill under fire over antisemitism on campus: Jon Huntsman calls her resignation 'not even debatable' ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231208121401-jon-huntsman-091917.jpg?q=w_1110,c_fill",
            "source": "CNN",
            "category_within_source": "Economy",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.132213,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "0.143956",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.06179",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOX",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "-0.32599",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.06179",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Transdermal Patches Market is Expected to Reach $8.0 Billion | MarketsandMarkets.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36151396/transdermal-patches-market-is-expected-to-reach-8-0-billion-marketsandmarkets",
            "time_published": "20231208T123000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Chicago, Dec. 08, 2023 ( GLOBE NEWSWIRE ) -- Transdermal Patches market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $8.0 billion by 2029, growing at a CAGR of 4.5% from 2023 to 2029 according to a latest report published by MarketsandMarkets™.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.155809,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NDEKF",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AGRX",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VTRS",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HKMPF",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LYPHF",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMRX",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ENDPQ",
                    "relevance_score": "0.031529",
                    "ticker_sentiment_score": "0.006513",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Bispecific Antibody Therapeutics Contract Manufacturing Market Size to Expand Lucratively and Reach $82.85 Bn to 2031 - Explained Details | Updated InsightAce Study",
            "url": "https://www.prnewswire.com/news-releases/global-bispecific-antibody-therapeutics-contract-manufacturing-market-size-to-expand-lucratively-and-reach-82-85-bn-to-2031---explained-details--updated-insightace-study-302009968.html",
            "time_published": "20231208T102000",
            "authors": [
                "InsightAce Analytics Pvt. Ltd."
            ],
            "summary": "Global Bispecific Antibody Therapeutics Contract Manufacturing Market Size to Expand Lucratively and Reach $82.85 ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.261838,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.041323",
                    "ticker_sentiment_score": "0.07774",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights",
            "url": "https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html",
            "time_published": "20231208T071400",
            "authors": [
                "Coherent Market Insights"
            ],
            "summary": "BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.",
            "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.196644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALPMF",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAK",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Walgreens' stock soars 8% to lead Dow gainers but is still on track for worst year since 1972",
            "url": "https://www.marketwatch.com/story/walgreens-stock-soars-8-to-lead-djia-and-s-p-500-gainers-but-is-still-on-track-for-worst-year-since-1972-dee951b5",
            "time_published": "20231207T204100",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Walgreens' stock rose ahead of a ruling on what scientific evidence can be cited in lawsuits alleging that use of Tylenol by pregnant women can lead to autism and ADHD in their children.",
            "banner_image": "https://images.mktw.net/im-712164/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.214829,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.079486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.079486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.079486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.107759",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "-0.079486",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why You Should Retain Boston Scientific  ( BSX )  Now",
            "url": "https://www.zacks.com/stock/news/2195111/heres-why-you-should-retain-boston-scientific-bsx-now",
            "time_published": "20231207T201400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990678"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                }
            ],
            "overall_sentiment_score": 0.325653,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EW",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.090277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.090277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.090277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.426225",
                    "ticker_sentiment_score": "0.484124",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.090277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.05535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.090277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HAE",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.090801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.148731",
                    "ticker_sentiment_score": "0.05535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXXXF",
                    "relevance_score": "0.049835",
                    "ticker_sentiment_score": "0.147548",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major donor calls on UPenn president to resign, threatens to rescind $100 million in stock | Business",
            "url": "https://www.cnn.com/2023/12/07/business/penn-emergency-meeting-liz-magill",
            "time_published": "20231207T175500",
            "authors": [
                "Matt Egan"
            ],
            "summary": "University of Pennsylvania board of trustees holds emergency meeting after president Liz Magill's disastrous testimony ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/ap23339671684398.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": -0.127659,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.148469",
                    "ticker_sentiment_score": "0.019588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BX",
                    "relevance_score": "0.021331",
                    "ticker_sentiment_score": "0.057627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOX",
                    "relevance_score": "0.021331",
                    "ticker_sentiment_score": "-0.306679",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.021331",
                    "ticker_sentiment_score": "0.057627",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company - Vanda Pharma  ( NASDAQ:VNDA ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36135531/vanda-pharmaceuticals-acquires-rights-to-multiple-sclerosis-drug-from-johnson-johnsons-company",
            "time_published": "20231207T173229",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Vanda Pharmaceuticals Inc VNDA has acquired U.S. and Canadian rights to Ponvory ( ponesimod ) from Actelion Pharmaceuticals Ltd, a Johnson & Johnson company JNJ.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/07/vnda.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.225659,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VNDA",
                    "relevance_score": "0.468029",
                    "ticker_sentiment_score": "0.18032",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.323078",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.323078",
                    "ticker_sentiment_score": "0.147595",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights' Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36138279/bms-attributes-sotyktu-falling-short-of-growth-expectations-to-access-but-recent-spherix-global-in",
            "time_published": "20231207T170124",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Exton, PA, Dec. 07, 2023 ( GLOBE NEWSWIRE ) -- While access took the forefront of BMS' response to Sotyktu ( deucravacitinib ) not meeting growth expectations during the company's Q3 earnings call, practicing dermatologists in Spherix research highlight safety as the leading, and growing, ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.150156,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VTYX",
                    "relevance_score": "0.03453",
                    "ticker_sentiment_score": "-0.006821",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.068995",
                    "ticker_sentiment_score": "0.236412",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": " ( JNJ )  - Analyzing Johnson & Johnson's Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/short-sellers/23/12/36134013/jnj-analyzing-johnson-johnsons-short-interest",
            "time_published": "20231207T141517",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Johnson & Johnson's JNJ short percent of float has fallen 8.33% since its last report. The company recently reported that it has 13.19 million shares sold short, which is 0.55% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.237013,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.081322",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biden administration asserts power to seize drug patents in move to slash high prices",
            "url": "https://www.cnbc.com/2023/12/07/biden-administration-asserts-power-to-seize-drug-patents.html",
            "time_published": "20231207T140003",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "The Biden administration unveiled a new framework outlining the factors federal agencies should consider in determining whether to use march-in rights.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107144414-1667342543138-bid.jpg?v=1675800915&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.152497,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "ALPMF",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "-0.257222",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "-0.164797",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.107978",
                    "ticker_sentiment_score": "-0.163652",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "-0.075771",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY®  ( ponesimod ) , a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis - Vanda Pharma  ( NASDAQ:VNDA ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/n36130427/vanda-pharmaceuticals-acquires-u-s-and-canadian-rights-to-ponvory-ponesimod-a-selective-s1p1r-modu",
            "time_published": "20231207T120000",
            "authors": [
                "PRNewswire"
            ],
            "summary": "WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ( Vanda ) VNDA today announced that it has acquired U.S. and Canadian rights to PONVORY® ( ponesimod ) from Actelion Pharmaceuticals Ltd. ( Janssen ) , a Johnson & Johnson Company. PONVORY® is approved by the U.S.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.147447,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VNDA",
                    "relevance_score": "0.084324",
                    "ticker_sentiment_score": "0.166663",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.028155",
                    "ticker_sentiment_score": "0.106145",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY®  ( ponesimod ) , a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis",
            "url": "https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-acquires-us-and-canadian-rights-to-ponvory-ponesimod-a-selective-s1p1r-modulator-approved-for-patients-with-relapsing-multiple-sclerosis-302008402.html",
            "time_published": "20231207T120000",
            "authors": [
                "Vanda Pharmaceuticals Inc."
            ],
            "summary": "Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® ( ponesimod ) , a Selective S1P1R ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2090054/VandaLogo_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.152253,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VNDA",
                    "relevance_score": "0.08146",
                    "ticker_sentiment_score": "0.179224",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.027195",
                    "ticker_sentiment_score": "0.11855",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage",
            "url": "https://www.globenewswire.com/news-release/2023/12/07/2792212/0/en/Santhera-Appoints-Executive-Committee-Members-as-it-Transitions-into-Commercial-Stage.html",
            "time_published": "20231207T060000",
            "authors": [
                "Santhera Pharmaceuticals Holding AG"
            ],
            "summary": "Pratteln, Switzerland, December 7, 2023 - Santhera Pharmaceuticals ( SIX: SANN ) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer ( CCO ) and of Marc Schrader to Chief Technology Officer ( CTO ) . Both will join the six-member Executive Committee effective ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/63cd960e-70ce-4ba8-8984-92f72954c235",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.155244,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CPRX",
                    "relevance_score": "0.050254",
                    "ticker_sentiment_score": "0.115275",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.050254",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.050254",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Deadline in 2 Days for Kenvue Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Kenvue Inc.  ( KVUE )  Investors of Filing Deadline in Class Action Lawsuit - Kenvue  ( NYSE:KVUE ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36123024/deadline-in-2-days-for-kenvue-inc-investors-kessler-topaz-meltzer-check-llp-reminds-kenvue-inc-kvu",
            "time_published": "20231206T213324",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "RADNOR, Pa., Dec. 06, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Kenvue Inc. ( \"Kenvue\" ) KVUE. ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.096895,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.524949",
                    "ticker_sentiment_score": "-0.016687",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056943",
                    "ticker_sentiment_score": "0.129956",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "J&J  ( JNJ )  Announces 2024 and Long-Term Financial Outlook",
            "url": "https://www.zacks.com/stock/news/2194292/jj-jnj-announces-2024-and-long-term-financial-outlook",
            "time_published": "20231206T162900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.163494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.058625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.051207",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.286864",
                    "ticker_sentiment_score": "0.029825",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36114393/jnj-ceo-signals-no-rush-into-weight-loss-drug-realm-emphasizes-different-priorities",
            "time_published": "20231206T162336",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Johnson & Johnson JNJ has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer Joaquin Duato highlighted. During the firm's investor day on Tuesday, Duato emphasized that the company's priorities lie in extensive expansion, ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/06/jnjioffice3.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.08561,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.164786",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.337197",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.164786",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "-0.148264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks",
            "url": "https://www.zacks.com/stock/news/2193912/the-zacks-analyst-blog-highlights-johnson-johnson-t-mobile-us-caterpillar-broadcom-and-starbucks",
            "time_published": "20231206T092900",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.285873,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TMUS",
                    "relevance_score": "0.196344",
                    "ticker_sentiment_score": "0.050169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.038803",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.131643",
                    "ticker_sentiment_score": "0.038803",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.321393",
                    "ticker_sentiment_score": "0.244696",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.259727",
                    "ticker_sentiment_score": "0.161487",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What HR Functions Can Companies Automate With AI?",
            "url": "https://www.forbes.com/sites/bernardmarr/2023/12/06/what-hr-functions-can-companies-automate-with-ai/",
            "time_published": "20231206T080923",
            "authors": [
                "Bernard Marr"
            ],
            "summary": "HR teams have moved beyond administrative and personnel-focused duties and are now leveraging data, analytics, and artificial intelligence ( AI ) to create sweeping changes in the way companies manage people. Automation is a key driver of these changes.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65702c007de42bc9179d871c/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.25535,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.0864",
                    "ticker_sentiment_score": "0.168855",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Healthcare education solutions market recorded 8.25% growth between 2021 and 2022 | 3M Corp, B. Braun SE ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/healthcare-education-solutions-market-recorded-8-25-growth-between-2021-and-2022--3m-corp-b-braun-se-becton-dickinson-and-co-and-more-among-the-key-companies-in-the-market--technavio-302006885.html",
            "time_published": "20231206T023500",
            "authors": [],
            "summary": "Healthcare education solutions market recorded 8.25% growth between 2021 and 2022 | 3M Corp, B. Braun SE ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.25915,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZBH",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAJFF",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMAWF",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRKR",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OCPNF",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TMO",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.032078",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Sees a More Significant Dip Than Broader Market: Some Facts to Know",
            "url": "https://www.zacks.com/stock/news/2193851/johnson-johnson-jnj-sees-a-more-significant-dip-than-broader-market-some-facts-to-know",
            "time_published": "20231205T224510",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $158.55, marking a -0.21% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default239.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928769"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.235832,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "0.275502",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/fallopian-tube-cancer-therapeutics-market-size-to-grow-by-usd-832-01-million-from-2023-2028-abbvie-inc-amgen-inc-arrien-pharmaceuticals-llc-and-more-among-the-key-companies-in-the-market---technavio-302006567.html",
            "time_published": "20231205T221500",
            "authors": [],
            "summary": "Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.026585,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAX",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "-0.045307",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IMGN",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SEMHF",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLVSQ",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "-0.003",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Analyst Reports for Johnson & Johnson, T-Mobile & Caterpillar",
            "url": "https://www.zacks.com/research-daily/2193470/top-analyst-reports-for-johnson-johnson-t-mobile-caterpillar",
            "time_published": "20231205T201400",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.344928,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CAT",
                    "relevance_score": "0.175221",
                    "ticker_sentiment_score": "0.272864",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.088147",
                    "ticker_sentiment_score": "0.225055",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36099323/bsense-announces-the-clinical-candidate-nomination-of-bsen760-a-novel-dual-kv7-23-and-trpv1-modula",
            "time_published": "20231205T191308",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NESS ZIONA, Israel, Dec. 05, 2023 ( GLOBE NEWSWIRE ) -- Bsense Bio Therapeutics Ltd., a preclinical-stage biopharmaceutical company developing innovative small molecule drug candidates for sensory hyperexcitability disorders, today announced the clinical candidate nomination of their drug ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.063509,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.037155",
                    "ticker_sentiment_score": "0.163791",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson's Strategic Forecast: Targets 5%-6% Operational Sales Growth For FY24 - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/markets/equities/23/12/36098586/johnson-johnsons-strategic-forecast-targets-5-6-operational-sales-growth-for-fy24",
            "time_published": "20231205T191257",
            "authors": [
                "Nabaparna Bhattacharya"
            ],
            "summary": "Johnson & Johnson JNJ expects operational sales growth in the range of 5%-6% for FY24. The company forecasts adjusted operational earnings per share growth of 7.3% at the midpoint with a range of $10.55-$10.75.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/jnj_1.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.29964,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.509654",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson sees 2024 sales growth slowing as top drug faces rivals",
            "url": "https://www.business-standard.com/companies/news/johnson-johnson-sees-2024-sales-growth-slowing-as-top-drug-faces-rivals-123120501287_1.html",
            "time_published": "20231205T164050",
            "authors": [
                "Bloomberg"
            ],
            "summary": "Johnson & Johnson expects operational sales growth to slow in 2024 as its top-selling psoriasis drug starts to face generic competition outside the US. The company forecasts between 5% to 6% operational sales growth next year, compared with its 8.5%-to-9% outlook for this year.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/05/full/1701794396-0294.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.224331,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.178459",
                    "ticker_sentiment_score": "0.037466",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Boston Scientific  ( BSX )  Gains From Global Expansion, FX Woe Ails",
            "url": "https://www.zacks.com/stock/news/2193448/boston-scientific-bsx-gains-from-global-expansion-fx-woe-ails",
            "time_published": "20231205T133000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                }
            ],
            "overall_sentiment_score": 0.219449,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "EW",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.061782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.061782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.061782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.538177",
                    "ticker_sentiment_score": "0.476395",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.061782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.134841",
                    "ticker_sentiment_score": "0.052418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.061782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HAE",
                    "relevance_score": "0.222838",
                    "ticker_sentiment_score": "0.084016",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.134841",
                    "ticker_sentiment_score": "0.052418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PXXXF",
                    "relevance_score": "0.045139",
                    "ticker_sentiment_score": "0.197268",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "J&J's  ( JNJ )  Bladder Cancer Drug Gets FDA's Breakthrough Tag",
            "url": "https://www.zacks.com/stock/news/2193403/jjs-jnj-bladder-cancer-drug-gets-fdas-breakthrough-tag",
            "time_published": "20231205T124000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.044131,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.05945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.302243",
                    "ticker_sentiment_score": "0.082988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.302243",
                    "ticker_sentiment_score": "-0.111678",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson forecasts as much as 6% sales growth in 2024",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-forecasts-much-6-sales-growth-2024-2023-12-05/",
            "time_published": "20231205T121700",
            "authors": [
                "Reuters"
            ],
            "summary": "Johnson & Johnson forecasts as much as 6% sales growth in ...",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/IBR4SY65JNIU5LXZZGQRSPUGXQ.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.098215,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.140896",
                    "ticker_sentiment_score": "0.191216",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Hospital Infection Therapeutics Market to be Worth USD 14.4 billion by 2031| Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36087772/hospital-infection-therapeutics-market-to-be-worth-usd-14-4-billion-by-2031-transparency-market-re",
            "time_published": "20231205T120000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, Dec. 05, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global hospital infection therapeutics market was estimated to have acquired US$ 11.3 billion in 2022.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.122221,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HKMPF",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.128169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.044551",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top legal practitioners who lead in their fields",
            "url": "https://www.ft.com/content/89690990-75f9-4172-97cb-b324407f639f",
            "time_published": "20231205T050059",
            "authors": [
                "Harriet Arnold"
            ],
            "summary": "The FT Innovative Lawyers awards seek out those who go beyond sheer prowess to address the nexus of the law, business and wider society ...",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F7e66a13b-3fc6-487d-b786-d1db22473820.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "Companies",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.15137,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.108033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CXW",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.020769",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "-0.15342",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BBBYQ",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "-0.023129",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WEWOW",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.132731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AIQUF",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.082639",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.132731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.104335",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.024126",
                    "ticker_sentiment_score": "0.078823",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation - JJDC, Inc.",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36080445/nanobiotix-announces-closing-of-the-remaining-4-8-million-investment-from-johnson-johnson-innovati",
            "time_published": "20231204T212241",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Aggregate gross proceeds of approximately €50.9 million ( equivalent to approximately $53.8 million ) received by NANOBIOTIX has increased to approximately €55.5 million ( equivalent to approximately $58.7 million ) extending its runway into mid' 2025",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Mergers",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                }
            ],
            "overall_sentiment_score": 0.145195,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.206685",
                    "ticker_sentiment_score": "0.031223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.020903",
                    "ticker_sentiment_score": "0.034299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NANO",
                    "relevance_score": "0.041791",
                    "ticker_sentiment_score": "0.059032",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation - JJDC, Inc.",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2790479/0/en/Nanobiotix-Announces-Closing-of-the-Remaining-4-8-Million-Investment-From-Johnson-Johnson-Innovation-JJDC-Inc.html",
            "time_published": "20231204T212200",
            "authors": [
                "Nanobiotix S.A."
            ],
            "summary": "PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO - NASDAQ: NBTX - \"Nanobiotix\" or the \"Company\" ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                }
            ],
            "overall_sentiment_score": 0.159205,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.208106",
                    "ticker_sentiment_score": "0.031433",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.02105",
                    "ticker_sentiment_score": "0.038126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NANO",
                    "relevance_score": "0.042085",
                    "ticker_sentiment_score": "0.064068",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation - JJDC, Inc.",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2790473/0/en/Nanobiotix-Announces-Closing-of-the-Remaining-4-8-Million-Investment-From-Johnson-Johnson-Innovation-JJDC-Inc.html",
            "time_published": "20231204T211600",
            "authors": [
                "Nanobiotix S.A."
            ],
            "summary": "PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO - NASDAQ: NBTX - \"Nanobiotix\" or the \"Company\" ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                }
            ],
            "overall_sentiment_score": 0.156756,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.193775",
                    "ticker_sentiment_score": "0.028123",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.03778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NANO",
                    "relevance_score": "0.039128",
                    "ticker_sentiment_score": "0.0636",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline - KVUE - Kenvue  ( NYSE:KVUE ) ",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36073621/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-kenvu",
            "time_published": "20231204T165606",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. ( \"Kenvue\" or the \"Company\" ) KVUE and certain officers.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.990678"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.976913"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.012007,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.502815",
                    "ticker_sentiment_score": "-0.060778",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.168021",
                    "ticker_sentiment_score": "0.015047",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Warren Buffett's Berkshire Hathaway Is Building a Stake in a \"Confidential\" Stock -- Could This Be It?",
            "url": "https://www.fool.com/investing/2023/12/04/warren-buffett-build-stake-in-confidential-stock/",
            "time_published": "20231204T100600",
            "authors": [
                "Sean Williams"
            ],
            "summary": "The Oracle of Omaha's company is requesting secrecy as it builds up its stake in one or more businesses.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756300%2Fbuffett9-tmf.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.176323,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "OXY",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.191623",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SU",
                    "relevance_score": "0.221145",
                    "ticker_sentiment_score": "0.158274",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.074576",
                    "ticker_sentiment_score": "0.16577",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KHC",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.168822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.037329",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SIRI",
                    "relevance_score": "0.148502",
                    "ticker_sentiment_score": "0.073249",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Disposable Medical Supplies Market to grow by USD 38.36 billion from 2022 to 2027|3M Co., Ambu AS, Ansell Ltd., B ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/disposable-medical-supplies-market-to-grow-by-usd-38-36-billion-from-2022-to-20273m-co-ambu-as-ansell-ltd-bbraun-se-and-more-among-the-key-companies-in-the-market--technavio-302003976.html",
            "time_published": "20231204T081500",
            "authors": [],
            "summary": "Disposable Medical Supplies Market to grow by USD 38.36 billion from 2022 to 2027|3M Co., Ambu AS, Ansell Ltd., B ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.136921,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SEIGF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TFX",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ICUI",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MMM",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNN",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRUMF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANSLF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMBBY",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMGKF",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.076844",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}